HC Wainwright Brokers Lower Earnings Estimates for Merus

Merus (NASDAQ:MRUS) – Equities research analysts at HC Wainwright reduced their Q2 2025 earnings per share estimates for Merus in a report issued on Thursday, May 8th. HC Wainwright analyst A. Fein now forecasts that the biotechnology company will earn ($1.28) per share for the quarter, down from their prior estimate of ($1.24). HC Wainwright has a “Buy” rating and a $85.00 price target on the stock. The consensus estimate for Merus’ current full-year earnings is ($3.85) per share. HC Wainwright also issued estimates for Merus’ Q3 2025 earnings at ($1.19) EPS, Q4 2025 earnings at ($1.29) EPS, FY2025 earnings at ($5.15) EPS, FY2026 earnings at ($4.86) EPS, FY2027 earnings at ($3.60) EPS and FY2028 earnings at ($1.79) EPS.

Merus (NASDAQ:MRUS) last released its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported ($1.40) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.23). The company had revenue of $26.49 million during the quarter, compared to the consensus estimate of $7.82 million. Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%.

Other equities research analysts also recently issued research reports about the company. Guggenheim reiterated a “buy” rating and issued a $109.00 price objective on shares of Merus in a report on Friday, March 28th. William Blair reiterated an “outperform” rating on shares of Merus in a report on Monday, April 28th. Wells Fargo & Company lowered their price target on Merus from $91.00 to $89.00 and set an “overweight” rating for the company in a report on Thursday, May 8th. Bank of America lowered their price target on Merus from $73.00 to $70.00 and set a “buy” rating for the company in a report on Monday, March 10th. Finally, Needham & Company LLC restated a “buy” rating and issued a $83.00 price target on shares of Merus in a report on Wednesday, April 9th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $85.15.

Merus Trading Down 3.5%

NASDAQ MRUS opened at $40.92 on Monday. The stock has a 50-day simple moving average of $43.43 and a 200 day simple moving average of $43.96. The company has a market capitalization of $2.83 billion, a PE ratio of -10.36 and a beta of 0.94. Merus has a 12 month low of $33.19 and a 12 month high of $61.61.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of MRUS. Harbor Capital Advisors Inc. boosted its position in shares of Merus by 2.2% during the fourth quarter. Harbor Capital Advisors Inc. now owns 43,208 shares of the biotechnology company’s stock worth $1,817,000 after buying an additional 921 shares during the period. Harbour Capital Advisors LLC acquired a new position in shares of Merus during the fourth quarter worth about $360,000. Avior Wealth Management LLC acquired a new position in shares of Merus during the fourth quarter worth about $76,000. KBC Group NV boosted its position in shares of Merus by 4,583.6% during the fourth quarter. KBC Group NV now owns 57,234 shares of the biotechnology company’s stock worth $2,407,000 after buying an additional 56,012 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its position in Merus by 10.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,517 shares of the biotechnology company’s stock valued at $610,000 after purchasing an additional 1,398 shares during the last quarter. 96.14% of the stock is owned by institutional investors and hedge funds.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.